X4 Pharmaceuticals (XFOR) Other Non-Current Liabilities (2017 - 2025)
X4 Pharmaceuticals (XFOR) posted Other Non-Current Liabilities of $10000.0 for Q4 2025, down 98.96% on a QoQ basis from $959000.0 in Q3 2025, and down 99.93% year-over-year from $13.8 million in Q4 2024.
X4 Pharmaceuticals (XFOR) Other Non-Current Liabilities (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals' Other Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $10000.0 for Q4 2025.
- Quarterly Other Non-Current Liabilities fell 99.93% year-over-year to $10000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10000.0 (down 99.93% YoY) and the FY2025 annual result came in at $10000.0, down 99.93% from the prior year.
- Other Non-Current Liabilities was $10000.0 for Q4 2025 at X4 Pharmaceuticals, down from $959000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $29.4 million in Q1 2024 and bottomed at $10000.0 in Q4 2025.
- A 5-year average of $5.3 million and a median of $650000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities jumped 8310.86% — and 2025, when it plunged 99.93%.
- X4 Pharmaceuticals' Other Non-Current Liabilities stood at $496000.0 in 2021, then soared by 4234.68% to $21.5 million in 2022, then fell by 27.06% to $15.7 million in 2023, then decreased by 12.29% to $13.8 million in 2024, then plunged by 99.93% to $10000.0 in 2025.
- Business Quant data shows XFOR's Other Non-Current Liabilities at $10000.0 in Q4 2025, $959000.0 in Q3 2025, and $535000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | X4 Pharmaceuticals | 167.90 Mn | -49.15 Mn | 2.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10,000.00 |
| Sep 30, 2025 | 959,000.00 |
| Jun 30, 2025 | 535,000.00 |
| Mar 31, 2025 | 567,000.00 |
| Dec 31, 2024 | 13.76 Mn |
| Sep 30, 2024 | 11.09 Mn |
| Jun 30, 2024 | 979,000.00 |
| Mar 31, 2024 | 29.44 Mn |
| Dec 31, 2023 | 15.68 Mn |
| Sep 30, 2023 | 1.08 Mn |
| Jun 30, 2023 | 1.47 Mn |
| Mar 31, 2023 | 350,000.00 |
| Dec 31, 2022 | 21.50 Mn |
| Sep 30, 2022 | 312,000.00 |
| Jun 30, 2022 | 314,000.00 |
| Mar 31, 2022 | 650,000.00 |
| Sep 30, 2021 | 496,000.00 |
| Jun 30, 2021 | 434,000.00 |
| Mar 31, 2021 | 491,000.00 |
| Dec 31, 2020 | 462,000.00 |